QOS-54USE OF CANNABINOIDS IN THE PEDIATRIC CENTRAL NERVOUS SYSTEM TUMOR POPULATION

Abstract

Background: Cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), are a class of chemical components that are found in marijuana. Numerous studies in adults have examined the effects of cannabinoids in management of cancer-related symptoms, including nausea, anorexia, and pain. Interest in the lay community in the role of cannabinoids as anticancer therapy is increasing, as some pediatric central nervous system (CNS) tumors have been shown to express cannabinoid receptors. In addition, thepresenceofcannabinoidreceptorsonimmunecellssuggestsapotentialrole for cannabinoids as immunomodulators. Methods: A prospective observational study is underway in Colorado, USA to evaluate serially the impact of cannabinoids on quality of life of pediatric CNS tumor patients who selfmedicate with cannabinoid products using PedsQL 4.0 Generic Core Scales and Brain Tumor and Family Impact modules. Laboratory assessments of neutrophil and T-cell activity will be performed to determine whether cannabinoid use by children with CNS tumors affects immune function and alters risk for infection. Pharmacokinetic analyses of CBD, THC and associated metabolites are planned to gather data regarding metabolism of cannabinoid products in children. Diaries will collect exploratory information on cannabinoid use patterns. Neuropsychological testing is also planned. Results: To date,threepatients (1 medulloblastoma, 1 glioblastoma,and 1 diffuse astrocytoma) have been enrolled. Conclusions: Accrual is on track to enroll the planned 50 pediatric CNS tumor patients over three years. This novel study should contribute to the increasing understanding of the potential role of cannabinoids in pediatric neuro-oncology.